Many people are turning to cleansing conditioners. Why, you ask? Because many people are discovering that there are harsh sulfate chemicals inside of most shampoo products. The more common sulfate is sodium lauryl sulfate (SLS) which is used to help lift the grease out of the hair. Another problem is that with color treated hair, harsh sulfates can make your hair color fade quicker, and then more money is spent in the salon getting color re-done. Some are turning to a very basic form of “no-poo shampooing” of baking soda or apple cider vinegar. Others have taken a different approach by creating “Cleansing Conditioners“.
Chaz Dean is one of those creators with his product Wen.Wen is created with 5 simple ingredients: Glycerin, Chamomile Extract, Wild Cherry Bark, Rosemary Extract and Panthenol. Washing your hair with these natural ingredients, the hair is cleansed without using sulfates that tend to strip the hair of natural oils.
This way, the hair is cleansed, stays moisturized, is more manageable and color lasts longer.Other companies are catching on to the trend and are creating their own lines of cleansing conditioners as well, such as L’oreal Paris, Pantene Pro-V and TRESemme. Try it out for yourself and see what cleansing conditioners can do for your hair.
Clay B. Siegall is the president, CEO and chairman of the board of Seattle Genetics. He co-founded Seattle Genetics in 1998. The company zeroed in on targeted cancer treatment. The biotechnology company was built on a strong foundation of scientific innovation, extensive scientific research and drug development practices, as well as his deep passion to help patients. Dr. Clay has successfully led the company through various phases like developing antibody-drug conjugates (ADCs) and securing the FDA approval in 2011 for ADCETRIS, its first ADC product. Seattle Genetics has partnered with Takeda Pharmaceutical Company to sell ADCETRIS in more than 60 countries. The company is embarking on developing a pipeline of ADC treatments for cancer treatment. Over the years, he has used his leadership skills to engage in rigorous research and facilitate the development of new drugs.
His unique leadership skills have enabled Seattle Genetics to develop multiple strategic licenses for their ADC technology, including AbbVie, Roche, Pfizer and GlaxoSmithKline, which have produced over $325 million to date. There are over 20 ADC drugs in internal or collaborator program clinical development using Seattle Genetics’ technology. Dr. Siegall has also spearheaded capital-raising activities for the company. He has managed to raise more than $1.2 billion through private and public funding, including the successful initial public offering in 2001. Siegall is the director of Biomedical Association and Washington Biotechnology. He sits on the board of the Fred Hutchinson Cancer Research Business Alliance.
Clay graduated from Washington University and the University of Maryland with a PhD in Genetics and a B.S. in Zoology respectively. Between 1991 and 1997, he worked for Bristol-Myers Squibb Pharmaceutical Research Institute. In addition, he rendered his services for the National Cancer Institute and the National Institutes of Health. Clay is a member of the board of directors of Alder BioPharmaceuticals, Washington Roundtable and Ultragenyx Pharmaceuticals. Dr. Clay Siegall’s hard work and dedication to developing drugs has seen him win multiple awards and recognition. Some of these awards include the 2013 University of Maryland Alumnus of the Year for Math and Natural Sciences, and the Ernst & Young Entrepreneur of the Year for 2012 Pacific Northwest. Clay holds 15 patents. He has authored more than 70 publications.